Cantor Fitzgerald Forecasts BEAM FY2025 Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM) – Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Beam Therapeutics in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Bienkowski expects that the company will post earnings of ($3.48) per share for the year. Cantor Fitzgerald currently has a “Hold” rating on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.64) per share.

Beam Therapeutics (NASDAQ:BEAM) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.01). Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. The company had revenue of $14.30 million for the quarter, compared to analyst estimates of $14.52 million. During the same period last year, the company earned ($1.22) earnings per share. The business’s revenue for the quarter was down 16.9% compared to the same quarter last year.

BEAM has been the topic of a number of other research reports. Scotiabank initiated coverage on Beam Therapeutics in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $24.00 price objective on the stock. Sanford C. Bernstein upgraded shares of Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 7th. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Beam Therapeutics in a research note on Monday, December 9th. Leerink Partnrs upgraded Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 6th. Finally, Leerink Partners upgraded Beam Therapeutics from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $27.00 to $39.00 in a research report on Wednesday, November 6th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $47.67.

Beam Therapeutics Stock Down 1.0 %

NASDAQ:BEAM opened at $26.13 on Thursday. The company has a market capitalization of $2.16 billion, a PE ratio of -14.95 and a beta of 1.92. Beam Therapeutics has a 52-week low of $20.84 and a 52-week high of $49.50. The stock has a fifty day simple moving average of $26.33 and a 200-day simple moving average of $25.72.

Hedge Funds Weigh In On Beam Therapeutics

Institutional investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. increased its stake in Beam Therapeutics by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,981 shares of the company’s stock valued at $75,000 after acquiring an additional 524 shares during the period. Blue Trust Inc. raised its holdings in shares of Beam Therapeutics by 84.0% in the 3rd quarter. Blue Trust Inc. now owns 3,135 shares of the company’s stock worth $73,000 after buying an additional 1,431 shares in the last quarter. Quarry LP lifted its position in shares of Beam Therapeutics by 350.0% during the 2nd quarter. Quarry LP now owns 3,600 shares of the company’s stock worth $84,000 after buying an additional 2,800 shares during the period. Arcadia Investment Management Corp MI acquired a new stake in Beam Therapeutics in the 3rd quarter valued at $98,000. Finally, KBC Group NV grew its position in Beam Therapeutics by 103.2% in the fourth quarter. KBC Group NV now owns 4,143 shares of the company’s stock valued at $103,000 after acquiring an additional 2,104 shares during the period. 99.68% of the stock is currently owned by institutional investors.

Insider Transactions at Beam Therapeutics

In related news, insider Christine Bellon sold 1,241 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $24.68, for a total transaction of $30,627.88. Following the transaction, the insider now owns 102,968 shares in the company, valued at $2,541,250.24. This trade represents a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, President Giuseppe Ciaramella sold 51,110 shares of the company’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $26.36, for a total value of $1,347,259.60. Following the completion of the transaction, the president now owns 109,150 shares in the company, valued at $2,877,194. This represents a 31.89 % decrease in their position. The disclosure for this sale can be found here. Insiders own 4.20% of the company’s stock.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.